ANTIBIOTIC RESISTANCE: A GLOBAL PROBLEM AND BACTERIOPHAGE THERAPY AS AN ALTERNATIVE SOLUTION
Keywords:
antimicrobial resistance; AMR; bacteriophages; phage therapy; biofilm; multidrug-resistant bacteria; One Health.Abstract
Antimicrobial resistance (AMR) is the ability of bacteria to withstand the action of antibiotics, and the World Health Organization regards it as one of the most serious threats to global health. According to the Global Research on Antimicrobial Resistance (GRAM) study, AMR was directly responsible for 1.14 million deaths and associated with 4.71 million deaths in 2021; annual attributable deaths are forecast to reach 1.91 million by 2050. Resistance arises through enzymatic inactivation, target modification, efflux pumps, reduced membrane permeability, biofilm formation and horizontal gene transfer, and is accelerated by inappropriate and excessive antibiotic use. Drawing on the GRAM project and the WHO GLASS 2025 report, this narrative review examines the global burden of AMR, the factors driving its spread and the WHO priority pathogens. Bacteriophage therapy is analysed separately: its mechanism of action, advantages (high specificity, activity against multidrug-resistant strains and biofilms, synergy with antibiotics), clinical experience and unresolved challenges (narrow host range, phage resistance, limited randomised evidence). We conclude that phage therapy is a promising direction for infections caused by multidrug-resistant bacteria, but robust clinical evidence is still limited; it should be regarded as a complement to antibiotics within a comprehensive strategy.
References
1.Murray CJL, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399:629–655.
2.GBD 2021 Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. Lancet. 2024;404:1199–1226.
3.World Health Organization. Global antibiotic resistance surveillance report 2025. Geneva: WHO; 2025. ISBN 9789240116337.
4.World Health Organization. WHO Bacterial Priority Pathogens List, 2024. Geneva: WHO; 2024.
5.Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284:1318–1322.
6.Aslam B, Wang W, Arshad MI, et al. Antibiotic resistance: a rundown of a global crisis. Infect Drug Resist. 2018;11:1645–1658.
7.Strathdee SA, Hatfull GF, Mutalik VK, Schooley RT. Phage therapy: from biological mechanisms to future directions. Cell. 2023;186:17–31.
8.Chan BK, Sistrom M, Wertz JE, et al. Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci Rep. 2016;6:26717.
9.Jault P, Leclerc T, Jennes S, et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis. 2019;19:35–45.
10.Ibrahim R, Aranjani JM, Kalikot Valappil V, Nair G. Unveiling the potential of bacteriophage therapy: a systematic review. Future Sci OA. 2025. doi:10.1080/20565623.2025.2468114.
11.Stokes JM, Yang K, Swanson K, et al. A deep learning approach to antibiotic discovery. Cell. 2020;180:688–702.
12.United Nations General Assembly. Political declaration of the high-level meeting on antimicrobial resistance. New York: UN; 2024.
13.Pirnay JP, Djebara S, Steurs G, et al. Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study. Nat Microbiol. 2024;9:1434–1453. doi:10.1038/s41564-024-01705-x.
14.World Health Organization. AWaRe classification of antibiotics for evaluation and monitoring of use, 2023. Geneva: WHO; 2023.




United Kingdom
Germany
France
Uzbekistan
Türkiye
Kazakhstan
Kyrgyzstan
Turkmenistan
Azerbaijan
India
Republic of Korea
Japan
United States of America
Kosovo
Italy
Spain
Poland
Netherlands
Belgium
Sweden
Norway
Finland
Denmark
Switzerland
Austria
Czech Republic
Hungary
Romania
Bulgaria
Greece
Portugal